• 10:13
  • 17.12.2018

Свежая новость:  South Africa's ANC to elect new leader

Study sheds light on Zika nerve disorder
здоровье
17.12.2018

Study sheds light on Zika nerve disorder

узнать больше
A new study sheds light on how the mosquito-borne Zika virus causes a rare neurological condition, and the findings could have implications for companies working on Zika vaccines, US researchers say.

The Zika outbreak that swept through the Americas in 2015 and 2016 showed the virus could, in rare cases, cause Guillain-Barre, an auto-immune disorder in which the body attacks itself in the aftermath of an infection.

Since the Zika virus attacks nerve cells, scientists were not sure whether the Guillain-Barre cases they had seen in Zika patients were caused by an auto-immune response to the Zika infection or a direct attack by the virus on nerve cells.
Mistake you are making after exercise

In pregnant women, the virus infects foetal brain cells, resulting in the birth defect known as microcephaly.

To study the nerve disorder, Dr Tyler Sharp of the US Centers for Disease Control and Prevention's Dengue Branch in San Juan and colleagues in Puerto Rico examined the rare case of a 78-year-old man from San Juan who had been infected with Zika in 2016, developed Guillain-Barre then died.

An autopsy showed inflammation and erosion of the protective sheath known as myelin in two nerves, but no evidence of the Zika virus in nerve cells.
What’s with all the public sex?

"In this case, it looks like it was antibodies that led to destruction of that myelin sheath," said Sharp, whose study was published in Emerging Infectious Diseases.

Sharp said it suggested the mechanism that causes Guillain-Barre after a Zika infection was the same as in other cases of the nerve disorder.

He said the study raised a caution flag for companies testing experimental Zika vaccines. Although Guillain-Barre typically occurs in the aftermath of an infection, it has been known to occur in response to a vaccine.
UK surgeon wrote initials on livers

"Vaccine manufacturers do need to be thinking about Guillain-Barre as a potential outcome of vaccination against Zika," he said.
1196331
узнать больше